|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
California Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing CaliforniaLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Natera Inc.
| Natera Inc. 201 Industrial Road, Suite 410 San Carlos, CA 94070 | |
| | Phone: | (650) 249-9090 | Year Established: | 2004 | Ticker: | NTRA | Exchange: | NASDAQ | Main Contact: | Gautam Kollu, VP, Marketing & Business Development | | Other Contacts: | Michael C. Little, Ph.D., Senior VP, R&D Jimmy Cheng-Ho Lin, Ph.D., CSO, Oncology Styrmir Sigurjonsson, Ph.D., Director of Statistics Daniel Rabinowitz, LL.M., General Counsel Jennifer Keller, MS, MBA, CGC, VP, Clinical Affairs and Medical Education Matthew Hill, Ph.D., VP, Research Mike Brophy, CFO Paul R. Billings, M.D., Ph.D., CMO Jonathan Sheena, M.Eng, CTO Matthew Rabinowitz, Ph.D., CEO & Founder
| | Company Description | Natera (formerly Gene Security Network) is a genetic testing company that has developed a proprietary bioinformatics technology (Parental Support) to deliver accurate and comprehensive high throughput testing for reproductive indications from tiny quantities of DNA – as small as that from a single cell. Natera operates a CLIA laboratory in Redwood City, Calif., providing a host of preconception and prenatal genetic testing services. Test offerings include preimplantation genetic diagnosis to analyze chromosomal anomalies or inherited genetic conditions during an IVF cycle in order to select embryos with the highest probability of becoming healthy children; products of conception testing following miscarriage to rapidly and extensively analyze fetal chromosomes in order to understand the cause; and non-invasive prenatal testing to determine paternity or detect genetic disease by analyzing fragments of fetal DNA in a pregnant mother’s blood drawn in the first trimester. Non-invasive testing for paternity is currently available worldwide. Natera's clinical trial for non-invasive detection of chromosomal anomalies is funded by the NIH and is being conducted by the leaders in maternal-fetal medicine in the United States. | |
|
|
|
|
|